PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pharmacogenet Genomics. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
PMCID: PMC2896866
NIHMSID: NIHMS204362

Selective Serotonin Reuptake Inhibitors (SSRI) Pathway

Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter that influences multiple processes, including autonomic function, motor activity, hormone secretion, cognition, and complex processes associated with affection, emotion, and reward [1].

In the terminal axon of the serotonergic neuron, free tryptophan (TRP) is converted to 5-HT [2]. 5-HT synthesis is a two-step process catalyzed by tryptophan hydroxylase (TPH) and aromatic decarboxylase (DDC). TPH is the rate-limiting enzyme and exists in two isoforms TPH1 and TPH2. The TPH2 isoform is the predominant form in neuronal tissue [3], [4]. The 5-HT uptake into presynaptic storage vesicles is mediated by the vesicular monoamine transporter (SLC18A2). The transporter accumulates serotonin into synaptic vesicles using a proton gradient across the vesicular membrane [5]. 5-HT that is not stored in vesicles is degraded by monoamine oxidase A (MAOA) to 5-hydroxyindoleacetic acid (5-HIAA).

An action potential stimulates a calcium-dependent exocytotic release of serotonin from presynaptic vesicles into the synaptic cleft, where it interacts with both post- and presynaptic receptors. At the presynaptic side, 5-HT activates 5-hydroxytryptamine (serotonin) receptor 1A (HTR1A), B (HTR1B), and D (HTR1D), which results in an attenuation of the 5-HT exocytosis [2]. This feedback loop regulates the 5-HT concentration in the synaptic cleft and therefore, the extent of stimulation of various HTR receptor subclasses at the postsynaptic membrane [6]. Prolonged administration of selective serotonin reuptake inhibitors (SSRI) desensitizes these feedback loops. Thus, their regulatory effects on the serotonergic neurotransmission are weakened [7]. Postsynaptic HTR1 receptors (HTR1A, HTR1B, HTR1D, HTR1E, HTR1F) work together with HTR2 receptor subtypes (HTR2A, HTR2C) in mediating effector signals via activation of second messenger cascades [2]. Postsynaptic, the main signaling pathway for HTR1 receptor subtypes is via coupling of Gi/o protein alpha subunit (GNAI). This interaction decreases cyclic AMP formation by inhibiting adenylate cyclases (ADCY) [8]. After interaction with 5-HT, the main signaling linkage for the HTR2 receptor subpopulation is to activate phospholipase C (PLCB) through coupling of Gq/11 protein alpha (GNAQ) [8]. PLCB catalyzes the formation of myoinositol- 1, 4, 5-trisphosphate (IP3) and diacylglycerol (DAG) [9].The postsynaptic, ionotropic HTR3 receptor is a cation-specific ligand-gated ion channel, which does not activate a second messenger system [10]. The binding of 5-HT to this receptor depolarizes the postsynaptic membrane by sodium influx and potassium efflux, which is assumed to influence the activation of HTR2 receptors. HTR4, HTR6, and HTR7 primarily couple Gs protein alpha (GNAS), which results in an activation of adenylate cyclase, and consequently in an increase of cyclic AMP levels [9]. Further operational diversity is supported by the existence of a great number of splice and editing variants for several HTRs, their possible modulation by accessory proteins and chaperones, as well as their potential to form homo or heteromers both at the GPCR and at the ligand-gated channel level [11].

The amplification of all those second messenger signals in further downstream reactions leads to the mediation of neurotransmitter release from central serotonergic, noradrenergic, and dopaminergic neurons in the brain by regulating potassium channels, several protein kinases, and other calcium dependent signals. Chronic administration of antidepressant treatments have been reported to commonly increase the expression of brain-derived neurotrophic factor (BDNF), an activity-dependent secreted protein that is critical to organization of neuronal networks and synaptic plasticity [12], [13].

The solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 (SCL6A4) is responsible for terminating the action of 5-HT in the synaptic cleft. Released serotonin is transported back into the presynaptic terminals via this integral membrane protein. SCL6A4 is a member of the Na+/Cl−-dependent transporter family [14].

Four major classes of antidepressant drugs exist: monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRI), tricyclic compounds, and atypical antidepressant drugs [7]. To date, no comprehensive hypothesis concerning the antidepressant action for those therapies has been established [15]. Nonetheless, those drugs have one or more primary molecular targets in order to act. The molecular target for SSRI is SCL6A4, resulting in an inhibition of 5-HT reuptake in the presynapse from the synaptic cleft. The five SSRI fluoxetine, fluoxamine, paroxetine, sertraline, and citalopram vary in their pharmacological profile resulting in differential efficacy or side-effect profile for particular patients [16], [17], [18]. SSRI have a high affinity for 5-HT uptake transporters, low affinity for noradrenaline uptake transporters, and very low affinity for neurotransmitter receptors.

The observation that current antidepressant therapies need a sustained treatment of 2–4 weeks to be effective suggests that adaptive changes in both serotonergic and noradrenergic neurotransmission and downstream neural adaptation (e.g. the BDNF receptor signaling pathway) rather than only the elevation in synaptic monoamine levels itself are responsible for the therapeutic effects [19], [20].

Several genetic polymorphisms have been associated with therapeutic SSRI response and also with adverse reaction, including genetic variants of the SCL6A4, HTR1A, HTR2A, HTR3B, TPH, BDNF, and G-protein beta3 subunit [10], [13], [21], [22].

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Zhou M, Engel K, Wang J. Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain. Biochem Pharmacol. 2007;73:147–154. [PMC free article] [PubMed]
2. Struder HK, Weicker H. Physiology and pathophysiology of the serotonergic system and its implications on mental and physical performance. Part I. Int J Sports Med. 2001;22:467–481. [PubMed]
3. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003;299:76. [PubMed]
4. Sakowski SA, Geddes TJ, Thomas DM, Levi E, Hatfield JS, Kuhn DM. Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res. 2006;1085:11–18. [PubMed]
5. Hoffman BJ, Hansson SR, Mezey E, Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol. 1998;19:187–231. [PubMed]
6. Boadle-Biber MC. Regulation of serotonin synthesis. Prog Biophys Mol Biol. 1993;60:1–15. [PubMed]
7. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol. 1993;16:387–400. [PubMed]
8. Bockaert J, Claeysen S, Becamel C, Dumuis A, Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006;326:553–572. [PubMed]
9. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, Grewal JS, Garnovskaya MN. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther. 2001;92:179–212. [PubMed]
10. Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics. 2008;9:501–504. [PubMed]
11. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res. 2008;195:198–213. [PubMed]
12. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and nonantidepressant drug treatments. Brain Res. 2008;1211:37–43. [PMC free article] [PubMed]
13. Drago A, De Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics. 2009;3:257–274. [PMC free article] [PubMed]
14. Quick MW. Regulating the conducting states of a mammalian serotonin transporter. Neuron. 2003;40:537–549. [PubMed]
15. Donati RJ, Rasenick MM. G protein signaling and the molecular basis of antidepressant action. Life Sci. 2003;73:1–17. [PubMed]
16. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11–28. [PubMed]
17. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009 CD006117. [PubMed]
18. Demyttenaere K, Jaspers L. Review: Bupropion and SSRI-induced side effects. J Psychopharmacol. 2008;22:792–804. [PubMed]
19. Vidal R, Valdizan EM, Mostany R, Pazos A, Castro E. Long-term treatment with fluoxetine induces desensitization of 5-HT receptor-dependent signalling and functionality in rat brain. J Neurochem. 2009 [PubMed]
20. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 2009 [PubMed]
21. Serretti A, Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J. 2004;4:233–244. [PubMed]
22. Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy. 2009;29:822–831. [PubMed]